Data gathered: November 27
AI Stock Analysis - Calidi Biotherapeutics (CLDI)
Analysis generated November 27, 2024. Powered by Chat GPT.
Calidi Biotherapeutics is a cutting-edge biotech company that is focused on the development of novel cancer therapies. It's a leader in the field of oncolytic virus-based immunotherapies, with a strong emphasis on leveraging the power of the immune system to combat cancer. The company is known for its innovative approaches and has attracted significant attention from both researchers and investors. However, it is important to evaluate their financial performance and market sentiment to gauge investment potential.
Stock Alerts - Calidi Biotherapeutics (CLDI)
 |
Calidi Biotherapeutics | November 27 Price is up by 8.8% in the last 24h. |
|
Calidi Biotherapeutics | November 26 Price is down by -6.9% in the last 24h. |
|
Calidi Biotherapeutics | November 25 Price is down by -5.8% in the last 24h. |
|
Calidi Biotherapeutics | November 22 Price is down by -6.3% in the last 24h. |
Alternative Data for Calidi Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 876 | Sign up | Sign up | Sign up |
| Twitter Followers | 71 | Sign up | Sign up | Sign up |
| Twitter Mentions | 98 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 34 | Sign up | Sign up | Sign up |
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
| Price | $2.14 |
| Target Price | Sign up |
| Volume | 1,580,000 |
| Market Cap | $25M |
| Year Range | $0.83 - $6.95 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung CancerNovember 17 - Yahoo |
 |
### Calidi Biotherapeutics (NYSE: CLDI) Announces Completion of $7.5 Million Public OfferingSAN DIEGO, November 15, 2024 – Calidi Biotherapeutics Inc. (NYSE American: CLDI) successfully concluded a public offering, as detailed in the company’s recentNovember 17 - ETF Daily News |
 |
Head to Head Analysis: Cullinan Therapeutics (NASDAQ:CGEM) versus Calidi Biotherapeutics (NYSE:CLDI)November 16 - ETF Daily News |
|
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common StockNovember 15 - Yahoo |
|
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common StockNovember 13 - Yahoo |
|
Calidi Biotherapeutics Announces Proposed Public OfferingNovember 13 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 3.1M | -3.1M | -5.1M | -5.2M | -0.065 |
| Q2 '24 | 0 | 3.6M | -3.6M | -5.8M | -5.1M | -1.400 |
| Q1 '24 | 0 | 4M | -4M | -7.2M | -6.6M | -0.200 |
| Q4 '23 | 170,000 | 5.9M | -5.7M | -8.2M | -7.6M | -0.480 |
| Q3 '23 | 0 | 4M | -4.3M | -2M | -7.1M | -0.140 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Calidi Biotherapeutics (CLDI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Calidi Biotherapeutics?
The Market Cap of Calidi Biotherapeutics is $25M.
What is the current stock price of Calidi Biotherapeutics?
Currently, the price of one share of Calidi Biotherapeutics stock is $2.14.
How can I analyze the CLDI stock price chart for investment decisions?
The CLDI stock price chart above provides a comprehensive visual representation of Calidi Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Calidi Biotherapeutics shares. Our platform offers an up-to-date CLDI stock price chart, along with technical data analysis and alternative data insights.
Does CLDI offer dividends to its shareholders?
As of our latest update, Calidi Biotherapeutics (CLDI) does not offer dividends to its shareholders. Investors interested in Calidi Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Calidi Biotherapeutics?
Some of the similar stocks of Calidi Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.